Aldesleukin; Recombinant Modified Human interleukin-2

Specification

• Cat#: THP-0007
• Product Name: Aldesleukin; Recombinant Modified Human interleukin-2
• Cas No: 110942-02-4
• Description: The product, a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) The product is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
• Sequences: MAPTSSSTKKTQLQLEHLLLDLQMILNGINNYKNPKLTRMLTFKFYMPKKATELKHLQCLEEELKPLEEVLNLAQSKNFHLRPRDLISNINVIVLELKGSETTFMCEYADETATIVEFLNRWITFCQSIISTLT
• Species: Human
• Molecular Weight: 15314.8 Da
• Source: E. coli
• Purity: >99% by SDS-Page and HPLC analysis
• Formula: C690H1115N177O202S6
• Endotoxin: <0.001 EU per 1 μg of the peptide by the LAL method
• Biological Activity: 22000000 unit / vial
• Storage: Lyophilized protein should be stored at < -20°C, though stable at room temperature for 3 weeks. Reconstituted protein solution can be stored at 2-8 °C for 1 week. Aliquots of reconstituted samples are stable at < -20°C for 3 months.
• Application: For treatment of adults with metastatic renal cell carcinoma.

Pharmaceutical Information

• Pharmaceutical Application: Aldesleukin
• Targets: Target 1. Interleukin-2 receptor subunit beta; Target 2. Interleukin-2 receptor subunit alpha; Target 3. Cytokine receptor common subunit gamma; Enzyme 1. Prostaglandin G/H synthase 2; Enzyme 2. Cytosolic phospholipase A2; Enzyme 3. Cytochrome P450 3A4; Enzyme 4. Xanthine dehydrogenase/oxidase; Enzyme 5. Cytochrome P450 2E1